- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Aprea Therapeutics reports progress in cancer drug development | 10 | Investing.com | ||
| Do | Fortschritte bei Krebstherapie: Aprea Therapeutics meldet Studiendaten und sichert Liquidität | 3 | Investing.com Deutsch | ||
| Do | Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 | 80 | GlobeNewswire (Europe) | DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen | |
| 09.12. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12. | Aprea Therapeutics sichert sich 3,1 Mio. US-Dollar durch Privatplatzierung | 1 | Investing.com Deutsch | ||
| 09.12. | Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 3 | GlobeNewswire (USA) | ||
| 08.12. | Aprea Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| APREA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.10. | Aprea's WEE1 inhibitor shows disease stabilization in early trial | 1 | Investing.com | ||
| 24.10. | Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 | 165 | GlobeNewswire (Europe) | 3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in... ► Artikel lesen | |
| 24.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.10. | Aprea sets 1,100 mg dose for ATR inhibitor, shifts focus to combinations | 1 | Investing.com | ||
| 15.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.09. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Aprea Therapeutics GAAP EPS of -$0.53 | 1 | Seeking Alpha | ||
| 12.08. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update | 203 | GlobeNewswire (Europe) | Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor... ► Artikel lesen | |
| 12.08. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.06. | Aprea Therapeutics: Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with ... | 149 | GlobeNewswire (Europe) | Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti-PD-1 therapy Initial Phase 1 clinical... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,144 | -0,50 % | Aktien KW 50 FED spielt mit, Höchststände in Spuckweite, aber Schwung kommt nicht. News. Nordex. Softing. Circus. ThyssenKrupp. Hapag Lloyd. Evotec. Carl Zeiss Meditec. Rheinmetall. TKMS. Delivery Hero. Circus | Aktien: Zuerst wartete man auf die FED. Als diese dann Mittwoch entsprechend der Markterwartung die Zinsen um 0,25% senkte, gab es in Folge zwar neue Hochs in USA, in Europa leichtes Plus, aber weit... ► Artikel lesen | |
| BB BIOTECH | 47,900 | -1,03 % | Jade Biosciences secures $45 million in private placement from BB Biotech | ||
| CUREVAC | 3,650 | -0,38 % | BioNTech SE: BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld | BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen... ► Artikel lesen | |
| VALNEVA | 3,492 | -0,29 % | Morgen-Update: Valneva-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| BIOGEN | 145,15 | +0,14 % | Biogen stock rated Outperform by RBC Capital with $210 price target | ||
| ILLUMINA | 111,40 | +0,04 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| ABIVAX | 97,90 | +0,82 % | Abivax: Übernahme-Kandidat unter der Lupe | Die Aktie von Abivax sorgte jüngst durch Übernahme-Gerüchte für Aufmerksamkeit. Mitglieder des No Brainer Club feierten unterdessen einen Kursverdreifacher. Trotz des Preisanstiegs sehen Marktbeobachter... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,200 | +2,13 % | Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment | Collaboration reduces time in fermenting complex bacterial strains, enabling continued focus on next-gen biological crop solutions.
BOSTON and PLANO, Texas, Dec.... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,910 | +2,82 % | Onco-Innovations Limited: Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care | VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce, further to its... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 79,63 | -2,97 % | Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital | ||
| QIAGEN | 38,445 | -0,09 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,14 | +0,37 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 269,26 | +1,28 % | Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer | ||
| APOGEE THERAPEUTICS | 77,35 | +2,41 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,900 | -3,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen |
APREA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,910 Euro und damit -0,02 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APREA THERAPEUTICS INC finden Sie auf Wallstreet Online.